INTRODUCTION
Estrogens regulate many essential physiological processes and are needed for the functional maintenance of many adult target tissues within and outside of the reproductive system. However, they can have deleterious actions in promoting breast and uterine cancers (1) (2) (3) (4) . This balance between desirable and undesirable activities in diverse target tissues offers an intriguing opportunity for the development of tissue-selective estrogens that provide a net benefit with minimal risk for menopausal hormone replacement, such as ones affording metabolic and vascular protection without stimulation of the breast or uterus. Estrogens act through estrogen receptors (ERs) by using two distinct signaling pathways, the nuclear-initiated ("genomic") pathway, wherein ER functions as a chromatin-binding ligandregulated transcription factor, and the extranuclear-initiated ("nongenomic") pathway, which involves kinase cascades initiated by ER action from outside the nucleus (5, 6) . Here, we used a process involving structural alteration of steroidal and nonsteroidal ER ligands in ways that enhanced their selectivity for the extranuclear-initiated pathway over the nuclear-initiated ER pathway, resulting in ER ligands having effective metabolic and vascular protective activity but lacking stimulatory activity on reproductive tissues.
The activation of specific kinases by the action of estrogens through extranuclear ER action is generally rapid and often transient (7) (8) (9) (10) (11) (12) , and its initiation likely requires only the input of a triggering signal by the ER-hormone complex to initiate a kinase cascade and cellular activities through the extranuclear-initiated ER signaling pathway that could collectively have important downstream cellular effects. By contrast, the activation of genes through the nuclear ER signaling pathway appears to require a sustained action of ER-hormone complexes, sufficient to effect dissociation of heat shock proteins, recruit co-regulator proteins, stimulate ER binding to chromatin, alter chromatin architecture and modify histones, and activate RNA polymerase (pol) II to initiate gene transcription. ER ligands with potent nuclear ER activity form kinetically stable receptor-cofactor complexes, and coactivator binding can slow ligand dissociation rates by orders of magnitude (13) . Thus, it seemed possible that ER ligands preferential for extranuclear over nuclear ER signaling might be obtained by redesigning the structures of certain estrogens in ways that would preserve their essential chemical features, a phenol and often a secondary alcohol, as well as their overall composition and geometry, but would reduce considerably their high-affinity ER binding. Our aim was to preserve the ability of such a modified estrogen to have an effective interaction with ER that would be appropriate and sufficient to activate the extranuclear-initiated ER pathway, but insufficient to sustain activity through the nuclear pathway.
Here, we describe the unique activities of such pathway preferential estrogens (PaPEs) that alter the balance of utilization of extranuclearand nuclear receptor-initiated signaling pathways. By selectively triggering extranuclear-initiated ER signaling pathway activities, PaPEs regulate the transcription of a subset of ER target genes and evoke biological outcomes both in cells in culture and in animals in vivo in ways that provide a favorable balance of desired versus undesired effects. Thus, PaPEs represent novel tissue-selective estrogens that might have potential as clinically useful pharmaceuticals. The structural alteration approach we have used to design PaPEs could be applied to other nuclear hormone receptors as well.
RESULTS

PaPE-1 has impeded ER binding and coactivator interactions
To create PaPE-1, we rearranged key elements of the steroid structure of estradiol (E 2 ) that, while preserving its key functional groups, reduced considerably its ER binding affinity (Fig. 1A) . First, we deleted the B-ring of the steroid, a change that we knew from previous work on A-CD and other B-seco estrogens would cause a drop in ER binding affinity (14) . Second, we added the two carbon atoms lost from the B-ring deletion to the A-ring, flanking both sides of the phenol; this type of ortho substitution sterically impedes the important hydrogen bonds between the phenol and the glutamate and arginine residues (Glu 353 and Arg
394
) in the ER ligand-binding pocket and also reduces receptor binding (15) . Finally, we converted the C-ring to a benzene, simplifying the structure by eliminating the C-18 methyl group and at the same time creating a biphenyl system, a ligand core element that is present in various nonsteroidal estrogens (16, 17) . From a comparison of their properties (Fig. 1A) , it is evident that both E 2 and the structurally permuted estrogen, PaPE-1, have closely matched estrogenic functional groups and physical properties (composition, shape, size, volume, lipophilicity, and polar surface area) but very different binding affinities for ERa and ERb.
The relative binding affinity (RBA) values of E 2 and PaPE-1 (Fig. 1A) were obtained by a competitive radiometric binding assay using purified full-length human ERa and ERb (18) . The RBAs for E 2 are defined as 100, and relative to E 2 , PaPE-1 binds 50,000-fold less well to ERa and ERb (fig. S1A). The equivalent dissociation constant (K d ) values are 10 and 25 mM for PaPE-1 on ERa and ERb, respectively, compared to the subnanomolar K d values for E 2 . Thus, our design greatly lowered the ER binding affinities of PaPE-1 for both ERs and also greatly increased its dissociation rate from ERa (fig. S1B) while preserving as much as possible the physical and functional group attributes of E 2 .
A computational model showing the structural details of how the ligand-binding pocket of ERa accommodates PaPE-1 in comparison to E 2 is presented in Fig. 1B . Helices 3 and 6 constrict the A-ring end of the binding pocket, and E 2 (silver gray) forms hydrogen bonds to both , further stabilized by a crystallographic water (red dot) bridging these two residues. By contrast, the ortho-methyl groups of PaPE-1 (in yellow) introduce steric clashes with helices 3 and 6, inducing a substantial shift in ligand positioning. Although the A-ring OH of PaPE-1 maintains a hydrogen bond to Glu  353 and the crystallographic water still  bridges between Glu  353 and Arg   394 , direct ligand contact to Arg 394 is broken (ER structure in yellow). At the D-ring end of the pocket, there is also a subtle shift in the positioning of His 524 . Overall, it appears that the reduced volume of the PaPE-1 ligand and the increased planarity due to the aromatic C-ring mimetic result in fewer van der Waals contacts throughout the central region of the pocket. All of these changes with respect to the ER-E 2 complex are consistent with the greatly lower binding affinity of PaPE-1. Nevertheless, the overall shape of the ligandbinding pocket is not altered in a major way by the binding of PaPE-1, suggesting that PaPE-1 can still form a structurally competent complex with ER.
Using a time-resolved Förster resonance energy transfer (FRET) assay we have previously developed, we monitored the binding of the steroid receptor coactivator 3 (SRC3) to ERa (19, 20) . In coactivator titration assays ( fig. S1C ), SRC3 bound with high affinity to ERa complexes with E 2 but showed no binding to ERa complexes with PaPE-1. Notably, however, the antagonist trans-hydroxytamoxifen (OH-Tam) reversed the ER-SRC3 interaction promoted by E 2 ; PaPE-1 also reversed the ER-SRC3 interaction, but only at much higher concentrations, commensurate with its lower ERa binding affinity ( fig. S1D) . The E 2 -elicited interaction of ERa with SRC3 was also observed by coimmunoprecipitation of the complexes from MCF-7 cells, whereas no coimmunoprecipitated complexes were observed for ERa and SRC3 after exposure to PaPE-1 ( fig. S1E ).
PaPE-1 regulates a subset of estrogen-modulated genes and activates kinases, but does not stimulate breast cancer cell proliferation
In earlier studies of an estrogen-dendrimer conjugate (EDC) that activates ER nongenomic signaling with high selectivity (8, 10, 21, 22) , we identified a set of genes in MCF-7 human breast cancer cells whose expression was increased effectively by either extranuclear or nuclear ER action, as well as ones that required only nuclear action by ER (10) . We found that PaPE-1 was selective in activating extranuclear-initiated ERregulated genes, as shown by LRRC54 stimulation, but was essential without activity on the nuclear-initiated ER gene target PgR ( Fig.  2A) . Activation of LRRC54 gene expression by PaPE-1 was blocked by treatment with the antiestrogen fulvestrant (ICI 182,780) (Fig. 2B ) and by knockdown of ERa (Fig. 2C and fig. S2 ). By contrast, knockdown of GPR30 did not affect gene stimulation (Fig. 2C and fig. S2 ). PaPE-1 also Quantitation of signal intensities is shown in the graph (n = 3 biological replicates). Two-way analysis of variance (ANOVA), Bonferroni posttest, *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar, 50 mm.
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did not stimulate proliferation of MCF-7 cells, whereas E 2 potently stimulated proliferation (Fig. 2D ).
When we monitored activation of major signaling pathways in MCF-7 cells, we observed that PaPE-1 efficiently activated mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK) signaling (Fig. 2E) , as seen by increased phosphorylation of P70S6K and 4EBP1, which are associated with mTOR complex 1 (mTORC1) activation, increased phosphorylation of SGK1, which is associated with mTORC2 activation, and increased phosphorylation of MAPK. PaPE-1 increased phosphorylation of AKT and SREBP1 (sterol regulatory elementbinding protein 1) to a greater extent than E 2 . However, PaPE-1 did not detectably induce phosphorylation of Ser 118 in ERa, which was observed with E 2 (Fig. 2E ) and is associated with the mitogenic activity of ERa (23) .
The mTOR pathway is the major signaling system that senses the nutrient state of the environment and modulates metabolic functions in the cell. mTOR kinase is present in two distinct complexes, mTORC1 and mTORC2, which are distinguished by the presence of RAPTOR and RICTOR scaffolding proteins, respectively. It is thought that mTORC1 primarily modulates cell metabolism, whereas mTORC2 is principally involved in regulating the cytoskeleton and cell proliferation (24, 25) . To further characterize the mTOR activation by PaPE-1, we performed proximity ligation assays (PLAs) in MCF-7 cells and found that ERa interacted with RAPTOR to a greater extent in the presence of PaPE-1 than E 2 (Fig. 2F) . We did not detect any interaction between ERa and mTOR, or ERa and proline-rich AKT substrate of 40 kD (PRAS40), which is important in AKT and mTOR signaling, suggesting that ERa modulated the mTOR pathway through direct interactions with RAPTOR ( fig. S3 ).
PaPE-1 regulates metabolism-related genes in an mTOR and MAPK activity-dependent manner, but does not cause recruitment of ERa to chromatin Next, we performed RNA sequencing (RNA-seq) analysis to compare genes that were changed in their expression by PaPE-1 and/or E 2 . We treated MCF-7 cells with 10 nM E 2 or 1 mM PaPE-1 for 4 and 24 hours and compared genes regulated by each compound at these two time points (Fig. 3A) . At both times, E 2 regulated the expression of more genes than did PaPE-1, and the magnitude of gene regulation by E 2 was generally higher than that by PaPE-1. At 4 hours, E 2 regulated nearly 1500 genes, whereas PaPE-1 modulated expression of only 500 genes (Fig. 3A, upper Venn diagram). At 24 hours, about 3000 genes were regulated by E 2 , whereas PaPE-1 regulated about 2200 genes (Fig. 3A , lower Venn diagram). At both 4 and 24 hours, about three quarters of the genes regulated by PaPE-1 were also targets of E 2 . Notably, only E 2 increased the expression of mitosis genes and decreased the expression of apoptosis genes at 24 hours (table S1), consistent with our observation that PaPE-1 did not stimulate MCF-7 cell proliferation.
Next, we used pathway-selective inhibitors to assess the effect of mTOR or MAPK pathway activation on PaPE-and E 2 -mediated gene regulation. The mTOR pathway inhibitor PP242 blocked the regulation of~60% of PaPE-1-regulated genes, but only 40% of E 2 -regulated genes. Similarly, the MAPK inhibitor AZD6244 blocked almost 50% of PaPE-1-regulated genes, but only~23% of E 2 -regulated genes (Fig. 3B) . Examination of enriched gene ontology (GO) functions revealed that these inhibitors blocked E 2 regulation of cell migration-, immune-, cell cycle-, and angiogenesisrelated genes, whereas they blocked PaPE-1 regulation of genes involved in nucleotide metabolism, inflammatory response, noncoding RNA processing, amino acid transport, and glycoprotein metabolism (table S1).
To investigate the roles of ERa, extracellular signal-regulated kinase 2 (ERK2), and active RNA pol II recruitment in PaPE-1-mediated transcriptional events, we performed chromatin immunoprecipitation sequencing (ChIP-seq) analysis, which revealed that ERa was recruited to chromatin upon treatment of cells with E 2 , but not with PaPE-1 ( Fig. 3C and table  S2 ). PaPE-1 induced recruitment of ERK2 to the proximal promoter regions of genes, whereas E 2 caused recruitment of ERK2 to enhancer regions together with ERa. We observed distinct RNA pol II recruitment sites with PaPE-1, further suggesting that PaPE-1 induces transcriptional events through recruitment of RNA pol II without affecting ERa or ERK2 recruitment to enhancer regions of target genes. These distinct patterns of ERa, ERK2, and phosphorylation of Ser 5 in RNA pol II binding after cell treatment with vehicle, E 2 , and PaPE-1 are shown for the TFF1/pS2 and LRRC54/TSKU genes in Fig. 3C (right). The lack of ERa and ERK2 recruitment by PaPE-1 may be associated with the lack of effect of PaPE-1 on the phosphorylation of Ser 118 in ERa (Fig. 2E ).
PaPE-1 is a tissue-specific modulator of ER and mTOR signaling, with preferential estrogen-like activity in nonreproductive (metabolic and vascular) tissues
We next characterized the in vivo biological activities of PaPE-1 in ovariectomized female mice. Similar to E 2 , PaPE-1 was cleared rapidly after subcutaneous injection [half-time (t 1/2 )~1 hour; fig. S4A ]; so, to provide more prolonged exposure for in vivo studies, we used either administration by ALZET minipump or by a pellet containing PaPE-1, both implanted subcutaneously ( fig. S4B ). Mice at 8 weeks of age were ovariectomized, and after 2 weeks, they were treated with control vehicle, E 2 , or PaPE-1 for 3 weeks. Although E 2 was effective in increasing growth of the uterus, PaPE-1 did not exhibit any stimulatory effects on uterine weight (Fig.  4A) . As has been previously demonstrated (26), we observed that E 2 induced marked involution of the thymus, but PaPE-1, even at a high dose, had no effect on thymus size (Fig. 4A) . Likewise, PaPE-1 did not change mammary gland ductal morphology from that of vehicle control mice, whereas E 2 elicited marked ductal growth (elongation and branching) (Fig.  4B ). Of interest, however, both E 2 and PaPE-1 reduced the mammary gland adiposity that develops in mice after ovariectomy. This effect was associated with reduced adipocyte area after E 2 or PaPE-1 treatment (Fig. 4C ). Body weights of the mice increased after ovariectomy, as has been previously reported, and this increase in weight was suppressed by PaPE-1 and by E 2 over the 3-week period monitored (Fig. 5A ). Body weights were statistically lower in E 2 -and PaPE-1-treated mice than in vehicle control-treated animals, and the PaPE-1 and E 2 groups were not statistically different from one another. The reduction in body weight gain that we observed with PaPE-1 was not due to a change in food consumption (Fig. 5B) . Because of the anorexigenic effect of E 2 , there was an early drop in food intake in E 2 -treated animals, an effect that was not observed in PaPE-1-treated animals, suggesting that this effect did not trigger the differences in body weights and changes in the fat depots.
A major impact of PaPE-1 was on fat depots of the animals, as observed in EchoMRI measurements. Both E 2 and PaPE-1 greatly reduced fat mass, but total lean mass and water mass were increased only by E 2 and were not affected by PaPE-1, further indicating that PaPE-1 worked by changing overall adiposity rather than lean mass of the animals (Fig.  5C ). Hematoxylin and eosin (H&E) and Oil Red O staining of perigonadal adipose tissue (Fig. 5D ) highlighted the similar and marked estrogenic effects of both PaPE-1 and E 2 on this tissue. PaPE-1 and E 2 decreased the weight of all of the fat depots examined (Fig. 5E ). The weights of the perigonadal, perirenal, and subcutaneous adipose tissues were reduced by both ligands, but to a larger extent by E 2 at the dosages tested. Mesenteric adipose tissue weight was similarly reduced by both ligands, and both ligands also decreased triglyceride concentrations in blood (Fig. 5F) .
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PaPE-1 AZD6244 n = 490 RNA was isolated, and RNA-seq was performed. Regulated genes are considered to be those with P < 0.05 and expression fold change >2 (n = 2 biological replicates). (B) PaPE-1-mediated gene expression changes are sensitive to mTOR and MAPK pathway inhibitors. Effect of mTOR and MAPK inhibitors on gene regulation by E 2 and PaPE-1 in MCF-7 cells is shown. Cells were pretreated with PP242 or AZD6244 before treatment with E 2 or PaPE-1 in the presence or absence of inhibitors. RNA was isolated, and RNA-seq was performed. (P < 0.05, fold change >2; n = 2 biological replicates). (C) PaPE-1 does not induce recruitment of ERa or ERK2 to chromatin but stimulates recruitment of RNA pol II. MCF-7 cells were treated with E 2 or PaPE-1. ChIP-seq was performed for the indicated proteins. UCSC (University of California, Santa Cruz) genome tracks of cistromes in the presence of E 2 or PaPE-1 are shown (right panel) (n = 3 biological replicates that were pooled). bp, base pairs.
Ovariectomy resulted in increased lipid droplet accumulation in the liver, and E 2 or PaPE-1 decreased hepatocyte lipid content, as observed in Oil Red O staining of liver sections (Fig. 5G) . We verified changes in fatty acid synthesis pathways by monitoring two biomarkers of hepatic steatosis, FASN (27, 28) and SREBP1c (29, 30) , and found that expression of these genes was reduced after 3 weeks of E 2 or PaPE-1 treatment (Fig.   5H ). Expression of SREBP1 transcriptional targets, FASN, and the gene encoding the enzyme acetyl-coenzyme A (CoA) carboxylase a (ACACA), which catalyzes the carboxylation of acetyl-CoA to malonylCoA, the rate-limiting step in fatty acid synthesis, was decreased by 24 hours of PaPE-1 or E 2 treatment and remained low over the 2-week monitoring period (Fig.  5H) .
PaPE-1 and E2 show similarities and differences in gene expression and signaling pathway activations in multiple tissues in vivo PaPE-1 induced tissue-specific molecular changes in gene expression and signaling pathway activation patterns. To characterize these changes in the various tissues harvested from animals in long-term studies, we performed analysis of the expression of genes reported in the literature to be altered in liver, skeletal muscle, perigonadal fat, pancreas, and uterus. PaPE-1 and E 2 generated quite similar profiles in metabolic tissues, namely, in liver and skeletal muscle; in contrast, only E 2 induced gene expression changes in uterus (Fig. 6A) , consistent with the selective stimulatory actions of PaPE-1 in nonreproductive tissues.
To gain more mechanistic insight, we profiled the signaling pathways activated by E 2 and PaPE-1 in different tissues (Fig. 6B ). E 2 and PaPE-1 had similar pathway effects in nonreproductive tissues, whereas E 2 , but not PaPE-1, stimulated reproductive tissues (uterus and mammary gland). Furthermore, in metabolic tissues such as liver and skeletal muscle, both E 2 and PaPE-1 were effective in inducing mTOR signaling, as observed by S6 phosphorylation.
PaPE-1 activity is lost in ERa knockout mice
A select number of effects of E 2 and PaPE-1 on physiologic processes and gene expression were compared in wild-type and ERa knockout (ERKO) mice, in which the complete ERa gene was deleted ( fig. S5 ). Ovariectomized mice were treated with E 2 or PaPE-1 for 3 weeks, and the ability of E 2 or PaPE-1 to diminish the body weight gain after ovariectomy was lost in the ERKO mice ( fig. S5A ). As expected, E 2 did not stimulate uterine growth in ERKO mice (fig. S5B), and E 2 or PaPE-1 did not decrease blood triglycerides in these mice ( fig. S5C) . Furthermore, ERa mediated the suppression of FASN and SREBP1c gene expression by PaPE-1 or E 2 in the liver of wild-type mice, an effect that was lost in ERKO mice ( fig. S5D) . . Unlike E 2 , PaPE-1 does not change uterus or thymus weight and does not induce mammary gland ductal branching, but like E 2 , PaPE-1 reduces mammary gland adipocyte area. (A) PaPE-1 does not affect uterus or thymus weight. C57BL/6 mice were ovariectomized and then were given daily subcutaneous injections of E 2 or were implanted with PaPE-1 pellets for 4 days. Weights of uterus and thymus were monitored (n = 8 mice per treatment). Scale bars, 5 mm. (B) PaPE-1 stimulates minimal mammary ductal elongation but it greatly reduces adipocyte size in mammary gland. Ovariectomized C57BL/6 mice were implanted with E 2 or PaPE-1 pellets. Whole-mount stain (scale bars, 1 mm) and H&E stain (scale bars, 200 mm) of mammary gland are shown. (C) Mammary gland adipocyte area was calculated from the H&E images (n = 4 mice per treatment). A one-way ANOVA model was fitted to assess the contribution of ligand treatment on uterine weight, thymus weight, or mammary gland adipocyte area. When the main effects were statistically significant at a = 0.05, pairwise t tests with a Bonferroni correction were used to identify the treatments that were significantly different from each other. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
PaPE-1 and E2 show beneficial vascular effects
Estrogens have potential beneficial actions on vascular cells, as exemplified by in vivo studies of carotid artery reendothelialization after perivascular electric injury in female mice. After ovariectomy, mice were treated with vehicle, E 2 , or PaPE-1 for 18 days, at which time E 2 -and PaPE-1-treated mice were also administered a single dose of vehicle or the antiestrogen ICI 182,780. Three days later, carotid artery denudation was performed, and the mice received a second dose of vehicle or ICI 182,780, whereas E 2 or PaPE-1 was continued, and 72 hours after denudation, Evans blue dye was administered systemically to assess the remaining area of denudation in the intimal surface of the carotid artery (Fig. 7A, upper panel) . E 2 and PaPE-1 caused similar marked endothelial repair, as indicated by the minimal area of remaining denudation, and the responses elicited by E 2 and PaPE-1 were fully prevented by the antiestrogen fulvestrant (ICI 182,780) (Fig. 7A, lower  panel) . In the same animals, uterine weight, which was greatly elevated by E 2 , was unaffected by PaPE-1, and as expected, the antiestrogen ICI 182,780 blocked uterine stimulation by E 2 (Fig. 7B) .
To evaluate direct effects on endothelium, endothelial nitric oxide synthase (eNOS) activation was assessed by measuring the conversion of Fig. 5 . Like E 2 , PaPE-1 reduces the increase in body weight after ovariectomy and reduces adipose stores and blood triglyceride concentrations. (A) PaPE-1 is effective in normalizing body weight after ovariectomy. Ovariectomized C57BL/6 mice were implanted with pellets containing E 2 or PaPE-1 or vehicle control for 3 weeks (n = 8 mice per group). Animals were on a normal chow diet. Two-way ANOVA, Bonferroni posttest, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, comparing treatments to vehicle. (B) Food consumption for each mouse from (A) was monitored weekly. (C) Body composition for each mouse from (A) was monitored using EchoMRI at the end of 3 weeks. One-way ANOVA, NewmanKeuls posttest, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0. When the main effects were statistically significant at a = 0.05, pairwise t tests with a Bonferroni correction were used to identify the treatments that were significantly different from each other. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (22), and there was a comparable response to PaPE-1; the effects of both E 2 and PaPE-1 were fully attenuated by ICI 182,780 (Fig. 7C) .
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Fig. 6. Gene regulation and signaling pathway activations by PaPE-1 and E 2 in tissues in vivo. (A) Ovariectomized C57BL/6 mice were implanted with pellets containing E 2 and PaPE-1. Liver, skeletal muscle, perigonadal fat, pancreas, and uterus were harvested. RNA was isolated, and qPCR was performed for the indicated genes (n = 8 mice per treatment).
(B) PaPE-1 activates mTOR signaling (as monitored by increased phosphorylation of S6) in liver and skeletal muscle. Ovariectomized C57BL/6 mice were injected with E 2 (E) or PaPE-1 (P) for 2 hours. The indicated tissues were collected and subjected to Western blot analysis for phosphorylated S6 and MAPK1/2. b-Actin and total ERK2 were used as loading controls. Total MAPK1/2 and total P70S6K are also shown (n = 3 mice per treatment).
that are structurally related to PaPE-1 by being altered forms of the steroidal ligand E 2 , but having variations in the structure of what was originally the E 2 D-ring, namely, ring cleavage in PaPE-2 and ring enlargement in PaPE-3 (Fig. 1A) . To further diversify the structures of PaPEs, we also studied an additional ligand, PaPE-4; this PaPE is derived from a nonsteroidal estrogen, bisphenol A (BPA), and it retains the core bisphenol structure of BPA but has been modified to have reduced ER binding affinity by replacing one of the methyl groups with a polar bisamide substituent. The binding and physical properties of PaPE-2, PaPE-3, and PaPE-4 are given in Fig. 1A . All of the PaPEs showed similar biological activities in vitro and in vivo. They all caused preferential stimulation of extranuclear-initiated over nuclear gene activity (LRRC54 > PgR) compared to E 2 (10), which efficiently stimulated expression of both genes (Fig. 8A) . In contrast to E 2 , none of the PaPEs stimulated proliferation of MCF-7 cells over a broad concentration range tested (Fig. 8B) . All of the PaPEs increased activation of MAPK, mTOR, and AKT signaling pathways, as monitored by the phosphorylation of MAPK, P70S6, SREBP1, and AKT in these cells (Fig. 8, C  and D) . In endothelial cells, PaPE-2, PaPE-3, and PaPE-4 also increased NOS activity (Fig. 8E ), similar to E 2 and PaPE-1 (Fig. 7C) , and the NOS stimulation was fully blocked with the antiestrogen ICI 182,780. In vivo, the four PaPEs and E 2 reduced body weight gain after ovariectomy (Fig. 8F) , without altering food consumption (Fig. 8G ). In contrast, unlike E 2 , the four PaPEs did not elicit increases in uterine weight (Fig. 8H) . The reduction in body weight with the four PaPEs was largely due to a change in body fat mass, with little or no change in lean mass or water mass, as monitored by EchoMRI. E 2 reduced fat mass more markedly and increased lean mass and water mass (Fig. 8I ). These differential effects may account for the fact that the body weight of E 2 -treated animals matched that of the PaPE-treated animals.
DISCUSSION
The preferential extranuclear-initiated pathway activity of PaPEs results in a distinctive pharmacological outcome, favoring beneficial metabolic and vascular effects over reproductive tissue stimulation
Here, we present a new approach to develop small-molecule estrogens with a favorable profile of tissue-selective activity through preferential activation of the extranuclear-initiated signaling pathway over the nuclearinitiated pathway. This type of estrogen molecule was derived through a structural alteration process designed to preserve essential physical and functional features of E 2 or BPA, but purposefully lessen the high-affinity binding required for nuclear ER signaling.
Our analyses of cellular pathways and gene expression changes in response to PaPE-1 and E 2 treatments indicated that E 2 and the PaPE-1 ligand regulated certain common as well as various different groups of genes and biological processes. In MCF-7 breast cancer cells, PaPE-1 regulated genes involved in nucleotide, amino acid, and lipid metabolism, and induced RNA pol II recruitment to chromatin, but PaPE-1 did not induce ERa or ERK2 recruitment to gene enhancers or stimulate expression of proliferation-associated genes, as seen with E 2 . However, like E 2 , PaPE-1 strongly activated MAPK and mTOR pathways, and PaPE-1 relied on these pathways for a considerable fraction of its gene regulation on the basis of the effect of MAPK and mTOR inhibitors. These results suggest a role of kinase pathways for some of the transcriptional responses we observed, and that these kinases might be working through other transcription factors that are downstream of MAPK or mTOR signaling [such as cyclic adenosine monophosphate response element-binding protein (CREB)] to affect gene regulation. 
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V e h E 2 P a P E -1 P a P E -3 P a P E -4 P a P E -2 I n t a c t V e h E 2 P a P E -1 P a P E -2 P a P E -3 P a P E -4 I n t a c t V e h E 2 P a P E -1 P a P E -2 P a P E - (F) The PaPEs and E 2 reduce weight gain after ovariectomy in C57BL/6 mice. Ovariectomized animals received pellets of E 2 , the PaPE, or vehicle, and body weight was monitored over the next 3 weeks. A group of intact non-ovariectomized mice were included for comparison (n = 4 mice per group). A two-way ANOVA model was fitted to assess the contribution of ligand treatment and time of ligand treatment on body weight or food consumption. When the effects were statistically significant at a = 0.05, pairwise t tests with a Bonferroni correction were used to identify the treatments that were significantly different from each other. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (G) Food consumption of the mice in (F) was monitored over time. (H) Assessment of uterine weight gain in the ovariectomized C57BL/6 mice in (F) after 3 weeks of receiving E 2 or PaPE-1, PaPE-2, PaPE-3, and PaPE-4. One-way ANOVA, Newman-Keuls posttest, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (I) Fat mass, lean mass, and water mass were measured by EchoMRI at the end of the 3-week treatment period in the mice in (F). A one-way ANOVA model was fitted to assess the contribution of ligand treatment on gene expression, fat mass, lean mass, and water mass. When the main effects were statistically significant at a = 0.05, pairwise t tests with a Newman-Keuls correction were used to identify the treatments that were significantly different from each other. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
The preferential regulation of cellular responses through the extranuclear signaling pathway by PaPE-1 and the three other PaPEs resulted in distinctive biological outcomes, favoring metabolic actions in liver and adipose tissues and actions on the vasculature, with negligible if any stimulatory activity in reproductive tissues. Thus, PaPE-1 lacked estrogen-like activity on uterus, thymus, and mammary gland but closely mimicked the actions of E 2 in metabolic tissues and on the vasculature. Regarding the impact on adipose sites, it is notable that both PaPE-1 and E 2 reduced central fat depots (perigonadal and perirenal) that are associated with the metabolic syndrome and obesity in postmenopausal women (31) . All four PaPEs suppressed body weight gain after ovariectomy, although suppression by E 2 was more marked and was accompanied by an increase in lean mass and water mass not seen with PaPEs. PaPE-1 greatly reduced expression of liver genes associated with lipid synthesis (such as FASN and ACACA) and decreased blood triglyceride concentrations. Like E 2 , PaPE-1 also decreased the expression of the mRNA encoding the transcription factor SREBP1c, which plays a key role in lipogenesis. These effects required ERa and were lost in ERKO mice.
The design of PaPEs represents a new approach for developing estrogens with pathway-and tissue-selective activity
Previous efforts to prepare agents having tissue-selective activity have used three different mechanisms: differential interaction with co-regulators, differing activity on the two ER subtypes, and restricted tissue, cellular, or subcellular distribution. SERMs (selective ER modulators; such as tamoxifen, raloxifene, and bazedoxifene) have different amounts of partial agonist-antagonist activity in different target tissues, a result of differential engagement of co-regulator proteins in a target cell-and gene-specific manner (32) . ER subtype-selective ligands were developed to exploit the distinctly different tissue distributions of ERa and ERb (33) so as to regulate the different sets of genes and physiological outcomes controlled by these two ERs (9, 34, 35), a major focus being on ERb-selective compounds to avoid the proliferative drive of ERa in reproductive tissues (36) (37) (38) .
To activate the extranuclear-initiated pathways of ER action in preference to nuclear-initiated actions, we originally developed a synthetic hormone-polymer conjugate, denoted EDC, that bound well to ER but had little genomic activity because it was excluded from the nucleus due to its charge and polymeric size (8, 10) . Although EDC provided robust ER-mediated protection against vascular injury and cortical bone loss without stimulation of the uterus and breast cancer (21, 22) , its polymeric nature complicates its development as a pharmaceutical agent. Other approaches have been taken to obtain selective estrogen action by restricting the sites of hormone action (39) . Recent studies using transgenic animals with ER engineered to have only nuclear effects [NOER mouse (40) or C451A-ERa mouse (41)] or extranuclear, membrane-initiated effects [MOER mouse (42) ] have further highlighted that preferential activation of one or the other of these pathways can result in distinctive, often beneficial patterns of selectivity (40, (43) (44) (45) ; genetic engineering, however, is not a pharmaceutical approach. Hence, as described in this study, we were prompted to undertake a different approach to discover small molecules that would have preferential activity on the extranuclear signaling pathway and might be used ultimately as novel pharmaceutical agents in women for hormone replacement therapy without detrimental effects on reproductive tissues.
Little is known in any system about the intimate molecular details of how a ligand binds to and dissociates from a receptor, and how the dynamics of these physical interactions are coupled to the dynamics of downstream signal transduction events. In general, as binding affinity drops, the rate of ligand dissociation increases, whereas the rate of ligand association changes comparatively little. This has been characterized in some detail with a number of ER ligands having a spectrum of affinities (46) . Despite wide differences in their binding affinities, ER agonist association rate constants all fell within the relatively narrow, 5-fold range (1.3 × 10 6 to 6.0 × 10
), whereas their dissociation rates covered a >5000-fold range (from 5 × 10 −5 to 2.7 × 10
, with rates being inversely related to ligand-binding affinities. These dissociation rates corresponded to a half-life of the ER-ligand complex that ranged from several hours to under 1 min for ligands with progressively decreasing affinities (46) .
To investigate how ER ligand-binding dynamics were coupled with signal transduction pathways, we altered the structure of the steroidal estrogen E 2 to produce PaPE-1, PaPE-2, and PaPE-3, and modified the structure of the nonsteroidal estrogen BPA to produce PaPE-4, with a particular aim in mind. We wanted to retain, as much as possible, the key physical, functional, and structural features of active estrogens, so that they would still be recognized by the ER ligand-binding domain (LBD), but to greatly lower the affinity of their interaction with ER.
We anticipated that the short lifetime of these ER-PaPE complexes might be sufficient to activate extranuclear signaling pathways but would be less effective in activating nuclear action, the former requiring the triggering of kinase cascades, but the latter requiring an ER-ligand complex of sufficient lifetime to alter chromatin architecture and promote transcription. By our measurements, the dissociation rates of PaPE-1 and E 2 for ERa differed by nearly 2000-fold; the half-life of the ER-E 2 complex was nearly 30 hours, whereas that of the PaPE-1 complex was less than 1 min (fig. S1B). These measurements were done with purified ER proteins in a cell-free system, and one should consider that, in a cellular context, the interaction of ER-ligand complexes with other proteins, such as co-regulators, or signaling or scaffold proteins, such as seen with RAPTOR in these studies, might modulate the ligand-binding properties of PaPEs.
There have been other attempts to produce estrogens having pathway-selective activity (47, 48) , but these compounds had either mixed endocrine effects or had limited selectivity and in vivo efficacy (49) (50) (51) . Thus, the structural permutation and modification approaches we used to generate PaPEs appear to provide a robust way to produce small molecules having distinct pathway preferential activity that is matched by a pattern of favorable biological actions. All four of the PaPEs described in this report provide favorable actions in metabolic and vascular tissues by selective activation of signaling pathways critical for ERa action in these tissues, yet they fail to activate these pathways and increase growth of the uterus or proliferation of mammary tissue. The tissue-selective actions of the PaPEs appear to result from the greater retention of their activity through the extranuclear-initiated pathway than through the nuclear pathway.
Other features of the PaPEs are of note: Although the affinity of PaPE-1 and the other PaPEs for ER is about 50,000-fold less than that of E 2 , we were able to stimulate extranuclear ER effects using only~500-fold excess of PaPE-1 over E 2 , an observation suggesting that the extranuclear signaling pathway might depend to a lesser extent on the affinity of ligand for the receptor than the nuclear pathway. Also, whereas PaPE-1, PaPE-2, and PaPE-3, which were patterned after E 2 , all have physical characteristics (lipophilicity, polar surface area, volume, and so on) similar to that of E 2 , PaPE-4 is considerably larger and more polar than E 2 and the other PaPEs, yet it has biological activities similar to those of the other three PaPEs, suggesting that the class of PaPE-like compounds can cover a rather broad range of physical and structural characteristics.
Our studies with PaPEs establish a new conceptual framework for the development of novel PaPEs that might have promise as clinically useful pharmaceuticals for estrogen replacement therapy to improve the metabolic and vascular health of postmenopausal women without risk to the breast or uterus. Furthermore, our ligand structural permutation process, which defined a distinct class of tissue-and pathway-selective estrogens, might also have broad applicability to other nuclear hormone receptors such as the glucocorticoid and vitamin D receptors, and liver X receptor b, for example, which are similar to ER in mediating both nuclear and extranuclear processes (52) . Changes that reduce affinity but preserve essential bioactive structural features of drugs for other classes of drug receptors that operate through more than one signaling pathway might enable the development of drug analogs with an altered balance of cellular signaling pathway utilization and possibly favorable selective activity.
MATERIALS AND METHODS
Cell culture and siRNA treatments MCF-7 cells were obtained from and grown as recommended by the American Type Culture Collection. Receptor abundance was measured by qPCR and Western blotting, and gene expression and proliferative response to E 2 were monitored regularly. For experiments with E 2 and PaPE treatment, cells were maintained in phenol red-free tissue culture medium for at least 5 days before use. ERa knockdown experiments used the SMARTpool of four small interfering RNAs (siRNAs) from Dharmacon and siRNA from Santa Cruz Biotechnology and were performed as described (10) with 30 nM siControl or siERa or siGPR30 for 72 hours and resulted in knockdown of the corresponding mRNA and protein by greater than 80%. Primary bovine aortic endothelial cells were harvested, maintained, and used as previously described (22) .
Animals and ligand treatments
Studies used wild-type and ERKO mice in C57BL/6 background. All experiments involving animals were conducted in accordance with the National Institutes of Health standards for the use and care of animals, with protocols approved by the University of Illinois at Urbana-Champaign and the University of Texas Southwestern Medical Center. Wild-type C57BL/6 mice were purchased from The Jackson Laboratory/National Cancer Institute. ERKO mice with complete excision of ERa and wild-type littermates were obtained from Taconic and were used as described previously (53, 54) .
In studies of metabolic parameters and gene expression in vivo, ligands were administered to ovariectomized recipient mice by subcutaneous implantation of pellets containing compound mixed with cholesterol to a total weight of 20 mg. Animals were single-housed during the study. For 3-week studies, E 2 (Sigma-Aldrich) dosage (0.125 mg per pellet) was chosen on the basis of our previous findings (38) . In carotid artery reendothelialization experiments, compounds were delivered at a dose of 6 mg/day by a 4-week ALZET minipump (model 2006), as described (22) . Total body weight and food intake were monitored every week after ovariectomy. Body fat and lean mass composition were monitored at the end of 3 weeks using EchoMRI-700 Body Composition Analyzer (Echo Medical Systems), which enables one to quantify longitudinal body composition in the live animal.
Western blotting and ChIP assays
Western blot analysis used specific antibodies for ERa (HC-20; Santa Cruz Biotechnology); ERK2 (D-2; Santa Cruz Biotechnology); and pS6, pS6K, pmTOR, pRAPTOR, pRICTOR, and pMAPK (Cell Signaling). Coimmunoprecipitation assays used antibodies for SRC3 (C-20; Santa Cruz Biotechnology) and ERa (F10; Santa Cruz Biotechnology). ChIP assays were carried out as described (9, 11) . Antibodies used were for ERa (HC-20), ERK2 (D2 and C14; Santa Cruz Biotechnology), and pSer 5 RNA pol II (sc-47701; Santa Cruz Biotechnology). ChIP DNA was isolated using QIAquick PCR Purification Kit (Qiagen) and used for ChIP-seq analysis and qPCR. qPCR was used to calculate recruitment to the regions studied, as described (9) .
ChIP-seq analysis and clustering
For genome-wide ChIP-seq, the ChIP DNA was prepared from three biological replicates and pooled. Libraries were prepared according to Illumina Solexa ChIP-seq sample processing methods, and single-read sequencing was performed using the Illumina HiSeq 2000. Sequences generated were mapped uniquely onto the human genome (hg18) by Bowtie2 (9, 11) . MACS (model-based analysis of ChIP-seq) algorithm was used to identify enriched peak regions (default settings) with a P value cutoff of 6.0 × 10 −7 and false discovery rate of 0.01, as we have described (9) . The seqMINER density array method with a 500-bp window in both directions was used for the generation of clusters, or groups of loci having similar compositional features (9) . BED (Browser Extensible Data) files for each cluster were used for further analysis with Galaxy Cistrome integrative analysis tools (Venn diagram, conservation, CEAS).
RNA-seq transcriptional profiling
For gene expression analysis, total RNA was extracted from three biological replicates for each ligand treatment using TRIzol reagent and further cleaned using the RNeasy kit (Qiagen). Once the sample quality and replicate reproducibility were verified, two samples from each group were subjected to sequencing. RNA at a concentration of 100 ng/ml in nuclease-free water was used for library construction. Complementary DNA (cDNA) libraries were prepared with the mRNA TruSeq Kit (Illumina Inc.). Briefly, the polyadenylate-containing mRNA was purified from total RNA, RNA was fragmented, doublestranded cDNA was generated from fragmented RNA, and adapters were ligated to the ends.
The paired-end read data from the HiSeq 2000 were processed and analyzed through a series of steps. Base calling and demultiplexing of samples within each lane were done with Casava 1.8.2. FASTQ files were trimmed using FASTQ Trimmer (version 1.0.0). TopHat2 (version 0.5) (55) was used to map paired RNA-seq reads to version hg19 of the Homo sapiens reference genome in the UCSC genome browser (56) in conjunction with the RefSeq genome reference annotation (57) . Gene expression values (raw read counts) from BAM files were calculated using Strand NGS (version 2.1) quantification tool. Partial reads were considered, and option of detecting novel genes and exons was selected. Default parameters for finding novel exons and genes were specified. DESeq normalization algorithm using default values was selected. Differentially expressed genes were then determined by fold change and P value with Benjamini and Hochberg multiple test correction for each gene for each treatment relative to the vehicle control (9) . We considered genes with fold change >2 and Benjamini-Hochberg-adjusted P value less than or equal to 0.05 as statistically significant, differentially expressed. All RNA-seq data sets have been deposited with the National Center for Biotechnology Information (NCBI) under Gene Expression Omnibus (GEO) accession no. GSE73663.
Motif and GO category analysis
Overrepresented GO biological processes were determined by the Webbased DAVID bioinformatics resource database (58) , ClueGO, and Web-based GREAT software (59) . Motif enrichment analysis was done using SeqPos (60) .
Immunohistochemistry H&E staining and whole-mount staining were performed on paraffinembedded tissue sections (61) . Images were quantified by monitoring average cell size from three randomly chosen fields in Fiji software (http://fiji.sc/wiki/index.php/Fiji).
Immunofluorescence microscopy, PLAs in cells, and data analysis Cells treated with vehicle (0.1% EtOH), 10 nM E 2 , or 1 mM PaPE-1 for 15 min were washed in phosphate-buffered saline (PBS), fixed on glass coverslips, and incubated with antibodies against ERa (F10; Santa Cruz Biotechnology), pSer 5 RNA pol II (47701; Santa Cruz Biotechnology), or RAPTOR (Cell Signaling). The next day, a PLA was performed using the Duolink in situ kit (Olink Bioscience) according to the manufacturer's instructions, as described (62) . Briefly, overnight incubation with primary antibodies was followed by hybridization with two PLA probes at 37°C for 1 hour, and then by ligation for 15 min and amplification for 90 min at 37°C. A coverslip was mounted on each slide, and image acquisition and analysis were conducted. Samples were imaged using a 63×/1.4 oil differential interference contrast M27 objective in a Zeiss LSM 700 or 710 laser scanning confocal microscope. Images were obtained in a sequential manner using a 488-nm Ar (10 mW) laser line for PLA signal. The individual channels for 4′,6-diamidino-2-phenylindole (DAPI) and PLA signal were obtained using a sequential scanning mode to prevent bleed-through of the excitation signal. Laser power, gain, and offset were kept constant across the samples and scanned in a high-resolution format of 512 × 512 or 1024 × 1024 pixels with 2/4 frame averaging. Further quantification of the images used Fiji software (http://fiji.sc/wiki/index.php/Fiji) (63) . Briefly, images were converted to 8 bit for segmentation for each channel, and images were background-subtracted using a rolling ball method, with a pixel size of 100 and segmented using the DAPI channel.
Cell proliferation assays
Cells were seeded at 1000 cells per well in 96-well plates. On the second day, the cells were treated with 0.1% ethanol vehicle, 10 nM E 2 , or PaPE at the concentrations indicated and proliferation was assessed using WST-1 reagent (Roche) as described (9) . 
Pharmacokinetic analyses
For short-term studies, ovariectomized C57BL/6 mice were injected subcutaneously with 100 mg of PaPE-1 in 100-ml DMSO. Three mice were sacrificed at each time point, and 400 ml of blood was obtained from the abdominal aorta. Samples were centrifuged at 2000g for 10 min, and serum was collected. A 50-ml portion of each sample was submitted to the Metabolomics Center at the University of Illinois for analysis. For longer-term studies, ovariectomized C57BL/6 mice were implanted subcutaneously with a pellet fabricated with 8 mg of PaPE-1 and 12 mg of cholesterol. Blood samples (30 ml) were collected by tail snipping every week until the third week of treatment. Samples were centrifuged at 2000g for 10 min, and serum was collected. Serum (10 ml) was mixed with 40 ml of PBS and submitted to the Metabolomics Center for analysis. For analysis, a mass standard of PaPE-1 (labeled with three deuterium atoms) was added to each sample before analysis by liquid chromatography-mass spectrometry using the 5500 QTrap with Agilent 1200 high-performance liquid chromatography.
Carotid artery reendothelialization
Carotid artery reendothelialization was studied after perivascular electric injury in mice by assessing Evans blue dye uptake 72 hours after injury. Endothelial denudation and recovery after injury in this model have been confirmed by immunohistochemistry for von Willebrand factor (64) . At the time of ovariectomy at 8 to 9 weeks of age, female mice received intraperitoneal osmotic minipumps prepared to deliver E 2 (6 mg/day) or PaPE-1. Carotid artery denudation was performed 21 days later. In select studies, additional treatments included subcutaneous injections of vehicle or ICI 182,780 (360 mg per mouse) administered 3 days before carotid injury and on the day of injury. At the end of the study, uteri were also harvested and weighed.
Ligand dissociation assays
The fluorescence polarization or anisotropy characteristics of fluorescein attached to C530 in ERa, which is sensitive to the nature of the bound ligand, can be exploited to detect the dissociation of one ligand and the association of a second ligand, with the rate of ligand exchange being limited by the rate of dissociation of the initially bound ligand (65) . PaPE-1 gives an anisotropy value of about 20% lower than that of E 2 when bound to ER, and OH-Tam gives an 80% lower anisotropy value than E 2 when bound to the ER; so, these differences can be used to monitor the rate of dissociation of the initially bound ligand.
ERa-LBD, mutated to have one active cysteine at Cys
530
, was sitespecifically labeled with 5-iodoacetamidofluorescein (65) and then diluted into t/g [50 mM tris, 10% glycerol (pH 8)] buffer with 0.01 M mercaptoethanol and ovalbumin (0.03 mg/ml) added as a carrier protein to give 2 nM ER. To minimize homoFRET, a fivefold excess (10 nM) of unlabeled ERa-LBD (10 nM) was added, and the fluorescein-labeled and unlabeled ER dimers were allowed to exchange at room temperature in the dark for 1 hour, thereby producing dimers in which essentially only one monomer is fluoresceinlabeled. The ER was then bound with 100 nM E 2 , or 100 nM/RBA of PaPE-1; the RBA of PaPE-1 is 0.002%; therefore, 100 nM/RBA = 50 mM PaPE-1 was used. These samples were allowed to complete ligand binding at room temperature in the dark for 2.5 hours.
The anisotropy was measured on a Spex Fluorolog II cuvette-based fluorometer under constant wavelength conditions. The excitation was set at 488 nm and emission at 520 nm, under magic angle conditions, and three to five time points were taken for a zero time. To initiate the dissociation of PaPE-1, 300 nM E 2 was added to the PaPE-1 sample, and the time course of dissociation was subsequently followed by changes in anisotropy. Because of glycerol viscosity changes, there is a change in the protein anisotropy between room temperature and 5°C; therefore, care was taken to prechill the protein as well as the cuvette chamber to 5°C.
To measure the dissociation of E 2 , 300 nM E 2 was added to the preexchanged sample of fluorescein-labeled and unlabeled apo-ER dimer and allowed to bind for 2.5 hours, as above. The cuvette and chamber were chilled to 5°C, and after taking the zero time points, E 2 dissociation was initiated by adding 5 mM OH-Tam, and change in anisotropy was followed with time. The data for both dissociation experiments were fitted to an exponential decay function by linear regression using Prism 4.
Computational modeling of the complex of ERa with PaPE-1 or E 2
Starting from the ERa + E 2 crystal structure (PDB code: 1GWR), the structure preparation routine in MOE (Molecular Operating Environment; Chemical Computing Group) was used to fill missing loops and side chains and add explicit hydrogen atoms. A custom volume visualization code was used to create the binding volume for the ERa + E 2 structure, shown in slate blue in Fig. 1B ; the red dot is a structural water. The model of the binding of PaPE-1 was built by progressive generation of the PaPE-1 ligand structure from that of E 2 , coupled with progressive minimization of the LBD: Atoms were first deleted from E 2 to open the B-ring and convert the C-ring into an aromatic ring, but the two ortho-methyl groups on the A-ring were not yet added. At this stage, the positions of the ligand oxygen atoms and all protein atoms were fixed, and energy minimization was performed using the MMFF94× force field with a termination gradient cutoff of 0.1 kcal/(mol·Å) to obtain a low-energy conformation of the PaPE-1 ligand core. All atoms were then unfixed, and energy minimization was further performed while constraining protein backbones to optimize interactions with hydrogen-bonding side chains. After the two A-ring ortho-methyl groups were added, another energy minimization was performed with constrained backbone atoms, and then a final unconstrained energy minimization was performed, all to the same gradient cutoff. The resulting positions of the ligand and hydrogen-bonding residues are shown in yellow in Fig. 1B .
Statistical analyses
Data from in vivo animal metabolism studies were analyzed using either a one-way ANOVA model to compare different ligand effects or a two-way ANOVA model to compare time-dependent changes. For every main effect that was statistically significant at a = 0.05, pairwise t tests were conducted to determine which treatment levels were significantly different from each other. For these t tests, the Bonferroni correction was used to control the experiment-wise type I error rate at a = 0.05 followed by Bonferroni post hoc test using GraphPad Prism 6 for Windows (GraphPad Software). Differences were considered statistically significant if *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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